Suwon-si, South Korea

Dukho Chang

USPTO Granted Patents = 1 

Average Co-Inventor Count = 10.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Dukho Chang: Innovator in Neurodegenerative Disease Treatment

Introduction

Dukho Chang, a talented inventor based in Suwon-si, South Korea, has made significant contributions to the field of pharmaceuticals. With a focus on addressing neurodegenerative and motor neuron diseases, Chang's innovative ideas are paving the way for future treatments.

Latest Patents

Dukho Chang holds a patent for an "Edaravone prodrug compound and pharmaceutical use thereof in treatment or alleviation of neurodegenerative or motor neuron disease." This invention presents a novel prodrug of an edaravone compound or its pharmaceutically acceptable salt, along with a pharmaceutical composition that serves as an active ingredient. The application of this invention aims to provide effective treatment and relief for individuals suffering from these challenging diseases.

Career Highlights

Chang is currently associated with J2H Biotech Inc., where he works alongside a team committed to advancing biotechnology and pharmaceuticals. His dedication and expertise have contributed to the innovative projects undertaken by the company.

Collaborations

In his professional journey, Dukho Chang has collaborated with esteemed colleagues, including Jae-Sun Kim and Hyung-Chul Ryu. Their collective efforts in research and development help bolster the fight against neurodegenerative diseases, showcasing the importance of teamwork in driving innovation.

Conclusion

Dukho Chang stands as a prime example of how innovative thinking and collaboration can lead to breakthroughs in the treatment of complex medical conditions. His work continues to inspire the scientific community, demonstrating the potential impact of inventions in improving patient outcomes and quality of life.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…